Post-market Reviews of Medicines to treat PAH and bDMARDs to treat Chronic Plaque Psoriasis
Page last updated: 22 April 2016
A public submission process for the Post-market Reviews of:
- Pulmonary Arterial Hypertension (PAH) medicines; and
- biological Disease Modifying Anti-Rheumatic Drugs (bDMARDs) to treat Chronic Plaque Psoriasis
will be open between 2 May 2016 and 16 May 2016.
Interested organisations and individuals are invited to provide a submission addressing the Reviews Draft Terms of Reference. To make a submission to either of these reviews, please go to the relevant Public Consultation page:
- for PAH Medicines, or
- for bDMARDs.
The public submission process will be open for two weeks and will close at 5pm Monday, 16 May 2016.
